DOCSLIB.ORG

Artículos Científicos

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Artículos Científicos Editor: NOEL GONZÁLEZ GOTERA Número 164 Diseño: Lic. Roberto Chávez y Liuder Machado. Semana 291114 – 051214 Foto: Lic. Belkis Romeu e Instituto Finlay La Habana, Cuba. ARTÍCULOS CIENTÍFICOS Publicaciones incluidas en PubMED durante el período comprendido entre el 29 de noviembre y el 5 de diciembre de 2014. Con “vaccin*” en título: 256 artículos recuperados. Vacunas meningococo (Neisseria meningitidis) 13. Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac. Kristiansen PA, Ba A, Ouédraogo AS, Sanou I, Ouédraogo R, Sangaré L, Diomandé F, Kandolo D, Saga I, Misegades L, Clark TA, Préziosi MP, Caugant DA. BMC Infect Dis. 2014 Dec 4;14(1):663. [Epub ahead of print] PMID: 25472422 [PubMed - as supplied by publisher] Related citations Select item 25472209 54. Immunogenicity and Safety of Meningococcal C Conjugate Vaccine in Children and Adolescents Infected and Uninfected with Human Immunodeficiency Virus in Rio de Janeiro, Brazil. Frota AC, Milagres LG, Harrison LH, Ferreira B, Barreto DM, Pereira GS, Cruz AC, Pereira-Manfro W, de Oliveira RH, Abreu TF, Hofer CB. Pediatr Infect Dis J. 2014 Dec 3. [Epub ahead of print] PMID: 25461473 [PubMed - as supplied by publisher] Related citations Select item 25461243 1 144. Immunogenicity of meningococcal quadrivalent (serogroup A, C, W135 and Y) tetanus toxoid conjugate vaccine: Systematic review and meta-analysis. Pellegrino P, Perrone V, Radice S, Capuano A, Clementi E. Pharmacol Res. 2014 Oct 30. pii: S1043-6618(14)00167-4. doi: 10.1016/j.phrs.2014.10.006. [Epub ahead of print] Review. PMID: 25447792 [PubMed - as supplied by publisher] Related citations Select item 25447598 213. [Programming and implementation a meningitis vaccination campaign in Africa.] Pérez-Manchón D. Enferm Clin. 2014 Oct 24. pii: S1130-8621(14)00085-0. doi: 10.1016/j.enfcli.2014.06.002. [Epub ahead of print] Spanish. No abstract available. PMID: 25442122 [PubMed - as supplied by publisher] Related citations Select item 25441634 Vacunas BCG – ONCO BCG (Mycobacterium bovis) 28. BALB/c mice display more enhanced BCG vaccine induced Th1 and Th17 response than C57BL/6 mice but have equivalent protection. Garcia-Pelayo MC, Bachy VS, Kaveh DA, Hogarth PJ. Tuberculosis (Edinb). 2014 Nov 11. pii: S1472-9792(13)20294-5. doi: 10.1016/j.tube.2014.10.012. [Epub ahead of print] PMID: 25467292 [PubMed - as supplied by publisher] Free Article Related citations Select item 25466778 94. The effect of bacille Calmette-Guérin vaccination at birth on immune response in China. Pang Y, Kang W, Zhao A, Liu G, Du W, Xu M, Wang G, Zhao Y, Zheng S. Vaccine. 2014 Nov 6. pii: S0264-410X(14)01405-4. doi: 10.1016/j.vaccine.2014.10.030. [Epub ahead of print] PMID: 25454854 [PubMed - as supplied by publisher] 2 Related citations Select item 25454853 125. Effect of cationic liposomes on BCG trafficking and vaccine-induced immune responses following a subcutaneous immunization in mice. Derrick SC, Yang A, Parra M, Kolibab K, Morris SL. Vaccine. 2014 Nov 15. pii: S0264-410X(14)01516-3. doi: 10.1016/j.vaccine.2014.11.004. [Epub ahead of print] PMID: 25448108 [PubMed - as supplied by publisher] Related citations Select item 25448107 126. BCG vaccination-induced long-lasting control of Mycobacterium tuberculosis correlates with the accumulation of a novel population of CD4<sup>+</sup>IL- 17<sup>+</sup>TNF<sup>+</sup>IL-2<sup>+</sup> T cells. Cruz A, Torrado E, Carmona J, Fraga AG, Costa P, Rodrigues F, Appelberg R, Correia-Neves M, Cooper AM, Saraiva M, Pedrosa J, Castro AG. Vaccine. 2014 Nov 20. pii: S0264-410X(14)01537-0. doi: 10.1016/j.vaccine.2014.11.013. [Epub ahead of print] PMID: 25448107 [PubMed - as supplied by publisher] Related citations Select item 25448106 Vacunas neumococo (Streptococcus pneumoniae) 55. Nasopharyngeal carriage of Streptococcus pneumoniae in Romanian children before the introduction of the pneumococcal conjugated vaccination into the national immunization programme: a national, multi-centre, cross-sectional observational study. Luminos M, Dorobat O, Jugulete G, Popescu GA, Florea D, Draganescu A, Cercel AS, Rafila A; on behalf of the of the SP5000 study group. Int J Infect Dis. 2014 Oct 30;29C:169-173. doi: 10.1016/j.ijid.2014.08.020. [Epub ahead of print] PMID: 25461243 [PubMed - as supplied by publisher] Free Article Related citations Select item 25460825 110. Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine. 3 Hirose TE, Maluf EM, Rodrigues CO. J Pediatr (Rio J). 2014 Oct 16. pii: S0021-7557(14)00144-2. doi: 10.1016/j.jped.2014.07.002. [Epub ahead of print] PMID: 25451210 [PubMed - as supplied by publisher] Free Article Related citations Select item 25451136 120. Identification of Proteins in Streptococcus pneumoniae by Reverse Vaccinology and Genetic Diversity of These Proteins in Clinical Isolates. Argondizzo AP, da Mota FF, Pestana CP, Reis JN, de Miranda AB, Galler R, Medeiros MA. Appl Biochem Biotechnol. 2014 Dec 2. [Epub ahead of print] PMID: 25448632 [PubMed - as supplied by publisher] Related citations Select item 25448542 128. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D; the Microbiologists of the Epibac; the ORP Networks. Vaccine. 2014 Nov 20. pii: S0264-410X(14)01535-7. doi: 10.1016/j.vaccine.2014.11.011. [Epub ahead of print] PMID: 25448105 [PubMed - as supplied by publisher] Related citations Select item 25448104 130. Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan: An open-labeled randomized study. Namkoong H, Funatsu Y, Oishi K, Akeda Y, Hiraoka R, Takeshita K, Asami T, Yagi K, Kimizuka Y, Ishii M, Tasaka S, Suzuki Y, Iwata S, Betsuyaku T, Hasegawa N. Vaccine. 2014 Nov 22. pii: S0264-410X(14)01562-X. doi: 10.1016/j.vaccine.2014.11.023. [Epub ahead of print] PMID: 25448102 [PubMed - as supplied by publisher] Free Article Related citations 4 Select item 25448101 143. Evaluation of antibody levels over 3years after 23-valent pneumococcal polysaccharide vaccination in patients with pulmonary diseases receiving steroids and immunosuppressive agents. Akamatsu T, Inui N, Kusagaya H, Nakamura Y, Suda T, Chida K. Clin Biochem. 2014 Nov 13. pii: S0009-9120(14)00747-4. doi: 10.1016/j.clinbiochem.2014.11.005. [Epub ahead of print] PMID: 25448031 [PubMed - as supplied by publisher] Related citations Select item 25447792 169. Emergence of serogroup 15 Streptococcus pneumoniae of diverse genetic backgrounds following the introduction of pneumococcal conjugate vaccines in Hong Kong. Liyanapathirana V, Nelson EA, Ang I, Subramanian R, Ma H, Ip M. Diagn Microbiol Infect Dis. 2014 Oct 2. pii: S0732-8893(14)00408-8. doi: 10.1016/j.diagmicrobio.2014.09.028. [Epub ahead of print] PMID: 25445117 [PubMed - as supplied by publisher] Related citations Select item 25444836 Vacunas fiebre tifoidea (Salmonella typhi) 207. Effectiveness of the Typhoid Vi Vaccine in Overseas Travelers from England. Wagner KS, Freedman JL, Andrews NJ, Jones JA. J Travel Med. 2014 Nov 30. doi: 10.1111/jtm.12178. [Epub ahead of print] PMID: 25444695 [PubMed - as supplied by publisher] Related citations Select item 25444525 243. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly. Pakkanen SH, Kantele JM, Savolainen LE, Rombo L, Kantele A. Vaccine. 2014 Nov 26. pii: S0264-410X(14)01569-2. doi: 10.1016/j.vaccine.2014.11.030. [Epub ahead of print] PMID: 25433216 5 [PubMed - as supplied by publisher] Free Article Related citations Select item 25433189 Vacuna tuberculosis (Mycobacterium tuberculosis) 61. The present and future of tuberculosis vaccinations. Principi N, Esposito S. Tuberculosis (Edinb). 2014 Oct 22. pii: S1472-9792(14)20570-1. doi: 10.1016/j.tube.2014.10.004. [Epub ahead of print] Review. PMID: 25458613 [PubMed - as supplied by publisher] Related citations Select item 25458600 177. Maternal immunization with pneumococcal 9-valent conjugate vaccine and early infant otitis media. Daly KA, Scott Giebink G, Lindgren BR, Knox J, Haggerty BJ, Nordin J, Goetz S, Ferrieri P. Vaccine. 2014 Oct 30;32(51):6948-6955. doi: 10.1016/j.vaccine.2014.10.060. [Epub ahead of print] PMID: 25444821 [PubMed - as supplied by publisher] Related citations Select item 25444820 240. Assessment of phagosomes infected with Mycobacterium tuberculosis as a vaccine candidate against tuberculosis. Sharma A, Parihar P, Sharma J. Indian J Exp Biol. 2014 Nov;52(11):1090-7. PMID: 25434104 [PubMed - in process] Related citations Select item 25433619 246. TB vaccine development: where are we and why is it so difficult? Wilkie ME, McShane H. 6 Thorax. 2014 Nov 28. pii: thoraxjnl-2014-205202. doi: 10.1136/thoraxjnl-2014-205202. [Epub ahead of print] PMID: 25432943 [PubMed - as supplied by publisher] Free Article Related citations Select item 25432792 Vacuna tosferina (Bordetella pertussis) 85. Pertussis vaccine for adults: Knowledge, attitudes, and vaccine receipt among adults with children in the household. Suryadevara M, Bonville CA, Cibula DA, Valente M, Handel A, Domachowse JR, Domachowske JB. Vaccine. 2014 Oct 25;32(51):7000-7004. doi: 10.1016/j.vaccine.2014.10.018. [Epub ahead of print] PMID: 25454869 [PubMed - as supplied by publisher] Related citations Select item 25454867 195. What predicts postpartum pertussis booster vaccination? A controlled intervention trial. Hayles EH, Cooper SC, Wood N, Sinn J, Skinner SR. Vaccine. 2014 Nov 7. pii: S0264-410X(14)01464-9. doi: 10.1016/j.vaccine.2014.10.074. [Epub ahead of print] PMID: 25444794 [PubMed - as supplied by publisher] Related citations Select item 25444793 Vacunas cólera (Vibrio cholerae) 7. Comparative Effectiveness of Different Strategies of Oral Cholera Vaccination in Bangladesh: A Modeling Study.
Load more

Recommended publications
  • ABSTRACT FROMEN, CATHERINE ANN. Monodisperse, Uniformly
    ABSTRACT FROMEN, CATHERINE ANN. Monodisperse, Uniformly-Shaped Particles for Controlled Respiratory Vaccine Delivery. (Under the direction of Joseph M. DeSimone). The majority of the world’s most infectious diseases occur at the air-tissue interface called the mucosa, including HIV/AIDS, tuberculosis, measles, and bacterial or viral gut and respiratory infections. Despite this, vaccines have generally been developed for the systemic immune system and fail to provide protection at the mucosal site. Vaccine delivery directly to the lung mucosa could provide superior lung protection for many infectious diseases, such as TB or influenza, as well as systemic and therapeutic vaccines for diseases such as Dengue fever, asthma, or cancer. Specifically, precision engineered biomaterials are believed to offer tremendous opportunities for a new generation of vaccines. The goal of this approach is to leverage naturally occurring processes of the immune system to produce memory responses capable of rapidly destroy virulent pathogens without harmful exposure. Considerable knowledge of biomaterial properties and their interaction with the immune system of the lung is required for successful translation. The overall goal of this work was to fabricate and characterize nano- and micro- particles using the Particle Replication In Non-wetting Templates (PRINT) fabrication technique and optimize them as pulmonary vaccine carriers. The main objectives of this PhD research included (1) the development of a calibration-quality aerosol system using PRINT, the application of these calibration-quality aerosols to improve understanding of (2) shaped aerosols under flow and (3) their cellular fate in the lung, and (4) the application of this knowledge towards the development of a mucosal vaccine.
    [Show full text]
  • Dictionary of Epidemiology, 5Th Edition
    A Dictionary of Epidemiology This page intentionally left blank A Dictionary ofof Epidemiology Fifth Edition Edited for the International Epidemiological Association by Miquel Porta Professor of Preventive Medicine & Public Health School of Medicine, Universitat Autònoma de Barcelona Senior Scientist, Institut Municipal d’Investigació Mèdica Barcelona, Spain Adjunct Professor of Epidemiology, School of Public Health University of North Carolina at Chapel Hill Associate Editors Sander Greenland John M. Last 1 2008 1 Oxford University Press, Inc., publishes works that further Oxford University’s objective excellence in research, scholarship, and education Oxford New York Auckland Cape Town Dar es Salaam Hong Kong Karachi Kuala Lumpur Madrid Melbourne Mexico City Nairobi Shanghai Taipei Toronto With offi ces in Argentina Austria Brazil Chile Czech Republic France Greece Guatemala Hungary Italy Japan Poland Portugal Singapore South Korea Switzerland Thailand Turkey Ukraine Vietnam Copyright © 1983, 1988, 1995, 2001, 2008 International Epidemiological Association, Inc. Published by Oxford University Press, Inc. 198 Madison Avenue, New York, New York 10016 www.oup-usa.org All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of Oxford University Press. This edition was prepared with support from Esteve Foundation (Barcelona, Catalonia, Spain) (http://www.esteve.org) Library of Congress Cataloging-in-Publication Data A dictionary of epidemiology / edited for the International Epidemiological Association by Miquel Porta; associate editors, John M. Last . [et al.].—5th ed. p. cm. Includes bibliographical references and index. ISBN 978–0-19–531449–6 ISBN 978–0-19–531450–2 (pbk.) 1.
    [Show full text]
  • Global Vaccine Action Plan Monitoring, Evaluation & Accountability Secretariat Annual Report 2016 © World Health Organization 2016
    Global Vaccine Action Plan Monitoring, Evaluation & Accountability Secretariat Annual Report 2016 © World Health Organization 2016 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate borderlines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader.
    [Show full text]
  • Artículos Científicos
    Editor: NOEL GONZÁLEZ GOTERA Número 064 Diseño: Lic. Roberto Chávez y Liuder Machado. Semana 291212 - 040113 Foto: Lic. Belkis Romeu e Instituto Finlay La Habana, Cuba. ARTÍCULOS CIENTÍFICOS P ublicaciones incluidas en P ubMED durante el período comprendido entre el 29 de diciembre de 2012 y el 4 de enero de 2013. Total de artículos reuperados con “vaccin*” en título: 68 Vacunas meningococo (Neisseria meningitidis) 13. Up take of meningococcal va ccine in Arizona schoolchildren after implementation of school- entry immunization requirements. Simpson JE, Hills RA, Allwes D, Rasmussen L. Public Health Rep. 2013 Jan;128(1):37-45. PMID: 23277658 [PubMed - in process] Related citations 33. A cute Cerebellar Ataxia Following Meningococcal Group C Conjugate V accination. Cutroneo PM, Italiano D, Trifirò G, Tortorella G, Russo A, Isola S, Caputi AP, Spina E. J Child Neurol. 2012 Dec 28. [Epub ahead of print] PMID: 23275434 [PubMed - as supplied by publisher] Related citations 39. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer m embrane vesicle va ccine against serogroup B meningococcal disease. Kaaijk P, van Straaten I, van de Waterbeemd B, Boot EP, Levels LM, van Dijken HH, van den Dobbelsteen GP. 1 Vaccine. 2012 Dec 27. doi:pii: S0264-410X(12)01815-4. 10.1016/j.vaccine.2012.12.031. [Epub ahead of print] PMID: 23273968 [PubMed - as supplied by publisher] Related citations 40. P riorities for research on meningocccal disease and the impact of serogroup A va ccination in the African meningitis belt. [No authors listed] Vaccine. 2012 Dec 27. doi:pii: S0264-410X(12)01820-8.
    [Show full text]
  • TB Vaccine R&D Roadmap Background Document
    TB Vaccine R&D Roadmap Background Document Version: 4.0 Date: 10.12.2020 This document summarizes the state-of-the-art in research and development for new vaccines for tuberculosis (TB). It is meant as a background document for a TB Vaccine Research & Development Roadmap and support the various consultations that are being held as part of the process of its development.a This background document seeks to provide an overview of the TB vaccine development goals, the current vaccine R&D pipeline, issues in clinical development, (new) directions in discovery and preclinical research, and considerations about moving vaccine candidates through the pipeline. It is meant as a living document, that will be updated as the Roadmap development process goes along. It is not meant to be exhaustive but to provide the reader with sufficient background to understand the Roadmap’s considerations and recommendations. For more detail the reader is referred to a number of recent reviews on the topic 1 2 3 4 5 6. The recommendations for TB vaccine R&D recently published by a number of stakeholders in have been added as Annex 17. LIST OF ABBREVIATIONS BCG Bacille Calmette-Guérin CHIM Controlled human infection model DS-TB Drug-susceptible tuberculosis IAVI International AIDS Vaccine Initiative IGRA Interferon-gamma release assay MDR-TB Multidrug-resistant tuberculosis MIP Mycobacterium indicus pranii Mtb Mycobacterium tuberculosis NHP Non-human primate PDP product Development Partnership PoD Prevention of Disease (clinical endpoint) PoI Prevention of Infection (clinical endpoint) PoR Prevention of Recurrence (clinical endpoint) PPC Preferred Product Characteristic R&D Research and development TB Tuberculosis TBVI Tuberculosis Vaccine Initiative TST Tuberculin skin test WHO World Health Organization a The TB Vaccine R&D Roadmap is being developed by the Amsterdam Institute for Global health and Development and the World Health organization, with financial support from the European & Developing Countries Clinical Trials Partnership (EDCTP).
    [Show full text]
  • Immunological Considerations for COVID-19 Vaccine Strategies
    REVIEWS Immunological considerations for COVID-19 vaccine strategies Mangalakumari Jeyanathan1,2,3,5, Sam Afkhami1,2,3,5, Fiona Smaill2,3, Matthew S. Miller1,3,4, Brian D. Lichty 1,2 ✉ and Zhou Xing 1,2,3 ✉ Abstract | The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) is the most formidable challenge to humanity in a century. It is widely believed that prepandemic normalcy will never return until a safe and effective vaccine strategy becomes available and a global vaccination programme is implemented successfully. Here, we discuss the immunological principles that need to be taken into consideration in the development of COVID-19 vaccine strategies. On the basis of these principles, we examine the current COVID-19 vaccine candidates, their strengths and potential shortfalls, and make inferences about their chances of success. Finally, we discuss the scientific and practical challenges that will be faced in the process of developing a successful vaccine and the ways in which COVID-19 vaccine strategies may evolve over the next few years. The coronavirus disease 2019 (COVID-19) outbreak constitute a safe and immunologically effective COVID-19 was first reported in Wuhan, China, in late 2019 and, at vaccine strategy, how to define successful end points the time of writing this article, has since spread to 216 in vaccine efficacy testing and what to expect from countries and territories1. It has brought the world to a the global vaccine effort over the next few years. This standstill. The respiratory viral pathogen severe acute Review outlines the guiding immunological principles respiratory syndrome coronavirus 2 (SARS-CoV-2) has for the design of COVID-19 vaccine strategies and anal- infected at least 20.1 million individuals and killed more yses the current COVID-19 vaccine landscape and the than 737,000 people globally, and counting1.
    [Show full text]
  • Modelling the Cost-Effectiveness of a New Infant Vaccine to Prevent Tuberculosis Disease in Children in South Africa Liezl Channing and Edina Sinanovic*
    Channing and Sinanovic Cost Effectiveness and Resource Allocation 2014, 12:20 http://www.resource-allocation.com/content/12/1/20 RESEARCH Open Access Modelling the cost-effectiveness of a new infant vaccine to prevent tuberculosis disease in children in South Africa Liezl Channing and Edina Sinanovic* Abstract Background: Tuberculosis remains the leading cause of death in South Africa. A number of potential new TB vaccine candidates have been identified and are currently in clinical trials. One such candidate is MVA85A. This study aimed to estimate the cost-effectiveness of adding the MVA85A vaccine as a booster to the BCG vaccine in children from the perspective of the South African government. Methods: The cost-effectiveness was assessed by employing Decision Analytic Modelling, through the use of a Markov model. The model compared the existing strategy of BCG vaccination to a new strategy in which infants receive BCG and a booster vaccine, MVA85A, at 4 months of age. The costs and outcomes of the two strategies are estimated through modelling the vaccination of a hypothetical cohort of newborns and following them from birth through to 10 years of age, employing 6-monthly cycles. Results: The results of the cost-effectiveness analysis indicate that the MVA85A strategy is both more costly and more effective – there are fewer TB cases and deaths from TB than BCG alone. The South African government would need to spend an additional USD 1,105 for every additional TB case averted and USD 284,017 for every additional TB death averted. The threshold analysis shows that, if the efficacy of the MVA85A vaccine was 41.3% (instead of the current efficacy of 17.3%), the two strategies would have the same cost but more cases of TB and more deaths from TB would be prevented by adding the MVA85A vaccine to the BCG vaccine.
    [Show full text]
  • Nonhuman Adenoviral Vector-Based Platforms and Their Utility in Designing Next Generation of Vaccines for Infectious Diseases
    viruses Review Nonhuman Adenoviral Vector-Based Platforms and Their Utility in Designing Next Generation of Vaccines for Infectious Diseases Marwa Alhashimi †, Ahmed Elkashif † , Ekramy E. Sayedahmed and Suresh K. Mittal * Immunology and Infectious Disease, and Purdue University Center for Cancer Research, Department of Comparative Pathobiology, Purdue Institute for Inflammation, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907-2027, USA; [email protected] (M.A.); [email protected] (A.E.); [email protected] (E.E.S.) * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Several human adenoviral (Ad) vectors have been developed for vaccine delivery owing to their numerous advantages, including the feasibility of different vector designs, the robustness of elicited immune responses, safety, and scalability. To expand the repertoire of Ad vectors for receptor usage and circumvention of Ad vector immunity, the use of less prevalent human Ad types or nonhuman Ads were explored for vector design. Notably, many nonhuman Ad vectors have shown great promise in preclinical and clinical studies as vectors for vaccine delivery. This review describes the key features of several nonhuman Ad vector platforms and their implications in developing effective vaccines against infectious diseases. Citation: Alhashimi, M.; Elkashif, A.; Keywords: adenoviral vector; nonhuman adenoviral vector; viral vector; vaccine; infectious disease Sayedahmed, E.E.; Mittal, S.K. Nonhuman Adenoviral Vector-Based Platforms and Their Utility in Designing Next Generation of 1. Introduction Vaccines for Infectious Diseases. Adenoviruses (Ads) have been an invaluable tool for in vivo gene delivery, which has Viruses 2021, 13, 1493. https:// dramatically influenced the usefulness of Ad vectors for vaccine development and gene doi.org/10.3390/v13081493 therapy.
    [Show full text]
  • Frontrunners in the Race to Develop a SARS-Cov-2 Vaccine
    Canadian Journal of Microbiology Frontrunners in the race to develop a SARS-CoV-2 vaccine Journal: Canadian Journal of Microbiology Manuscript ID cjm-2020-0465.R1 Manuscript Type: Review Date Submitted by the 16-Nov-2020 Author: Complete List of Authors: Russell, Raquel; University of Manitoba, Department of Microbiology Pelka, Peter; University of Manitoba, Department of Microbiology Mark, Brian; University of Manitoba, Department of Microbiology Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV-2, Keyword: COVID-19,Draft vaccine development Is the invited manuscript for consideration in a Special Not applicable (regular submission) Issue? : © The Author(s) or their Institution(s) Page 1 of 91 Canadian Journal of Microbiology 1 2 3 Frontrunners in the race to develop a SARS-CoV-2 vaccine 4 5 Authors: Raquel L. Russell, Peter Pelka, Brian L. Mark 6 7 Affiliations: Department of Microbiology,Draft University of Manitoba, Winnipeg, 8 Manitoba, Canada, R3T2N2 9 10 Correspondence: Brian L. Mark, Ph.D., 11 email: [email protected] 12 tel: 1-204-480-1430 13 14 15 16 17 1 © The Author(s) or their Institution(s) Canadian Journal of Microbiology Page 2 of 91 1 Abstract 2 Numerous studies continue to be published on the COVID-19 pandemic that is being 3 caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Given the 4 rapidly evolving global response to SARS-CoV-2, here we primarily review the leading COVID- 5 19 vaccine strategies that are currently in Phase III clinical trials. Non-replicating viral vector 6 strategies, inactivated virus, recombinant protein subunit vaccines, and nucleic acid vaccine 7 platforms are all being pursued in an effort to combat the infection.
    [Show full text]
  • Cost-Effectiveness Analysis of Mva85a Vaccine: a New Tb Vaccine Candidate
    COST-EFFECTIVENESS ANALYSIS OF MVA85A VACCINE: A NEW TB VACCINE CANDIDATE by LIEZL BONNIN CHANNING CHNLIE001 SUBMITTED TO THE UNIVERSITY OF CAPE TOWN In partial fulfilment of the requirements for the degree ty of Cape Town Master of Public Health in Health Economics University of Cape Town (UCT) Universi August 2013 Supervisor: Dr Edina Sinanovic Health Economics Unit University of Cape Town South Africa The copyright of this thesis vests in the author. No quotation from it or information derived from it is to be published without full acknowledgement of the source. The thesis is to be used for private study or non- commercial research purposes only. Published by the University of Cape Town (UCT) in terms of the non-exclusive license granted to UCT by the author. University of Cape Town ty of Cape Town Universi DECLARATION I, Liezl Bonnin Channing (student number CHNLIE001), hereby declare that the work on which this dissertation/thesis is based is my original work (except where acknowledgements indicate otherwise) and that neither the whole work nor any part of it has been, is being, or is to be submitted for another degree in this or any other university. I empower the university to reproduce for the purpose of research either the whole or any portion of the contents in any manner whatsoever. Signature: Signature removed Date: 08 July 2013 ty of Cape Town Universi i Dedications To Dr Fareed Abdullah (affectionately known as “Dr”), thank you for taking a chance on me in 2003, for expanding my “pharmacist” horizons, for taking an interest in my professional development, and for investing in it, too! Without you, I would never have been exposed to the concepts of health economics, contemplated a degree in Public Health, or embarked upon a career in international health (financing!).
    [Show full text]
  • SUPPLEMENTARY INFORMATION Population Differences
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open 1 SUPPLEMENTARY INFORMATION 2 3 Population differences in vaccine responses (POPVAC): scientific rationale and cross-cutting 4 analyses for three linked, randomised controlled trials assessing the role, reversibility and 5 mediators of immunomodulation by chronic infections in the tropics 6 Gyaviira Nkurunungi1,¶,*, Ludoviko Zirimenya1,¶, Agnes Natukunda1,¶, Jacent Nassuuna1, Gloria 7 Oduru1, Caroline Ninsiima1, Christopher Zziwa1, Florence Akello1, Robert Kizindo1, Mirriam Akello1, 8 Pontiano Kaleebu1, Anne Wajja1, Henry Luzze2, Stephen Cose1,3, Emily L Webb4, Alison M Elliott1,5 for 9 the POPVAC trial team 10 11 1Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research 12 Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda 13 Research Unit, Entebbe, Uganda 14 2Uganda National Expanded Program on Immunisation, Ministry of Health, Kampala, Uganda 15 3Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United 16 Kingdom 17 4MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School 18 of Hygiene and Tropical Medicine, London, United Kingdom 19 ¶These authors contributed equally 20 *Correspondence: Gyaviira Nkurunungi; [email protected] Nkurunungi G, et al. BMJ Open 2021; 11:e040425. doi: 10.1136/bmjopen-2020-040425 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open 21 Table S1. Uganda National Expanded Programme on Immunisation (EPI) schedule Mode and site of Vaccine/ antigen Dosage and doses required Minimum Interval Between Doses Minimum Age to Start Storage Temperatures Administration Infant vaccines Infants (0-11m) 0.05ml.
    [Show full text]
  • Research Report 2000
    University of Cape Town RESEARCH REPORT 2000 Faculty of Health Sciences This report can also be found on UCT’s webpage: http://www.uct.ac.za Editor: Ms M. Ward CONTENTS FACULTY OF HEALTH SCIENCES Introduction 1 Department of Anaesthesia 8 Department of Anatomical Pathology 11 Department of Cardiothoracic Surgery 17 Department of Chemical Pathology 23 Department of Dermatology 28 Department of Forensic Medicine and Toxicology 32 Department of Haematology 35 Department of Human Biology 38 Department of Human Genetics 44 Department of Immunology 47 Department of Logopaedics 50 Department of Medical Biochemistry 53 Department of Medical Microbiology 56 Department of Medical Physics 61 Department of Medicine 63 Department of Neurosurgery 108 Department of Nuclear Medicine 110 Department of Nursing 112 Department of Obstetrics & Gynaecology 116 Department of Occupational Therapy 122 Department of Ophthalmology 126 Department of Orthopaedic Surgery 129 Department of Otolaryngology 134 Department of Paediatric Pathology 136 Department of Paediatric Surgery 140 Department of Paediatrics & Child Health 142 Department of Pharmacology 154 Department of Physiotherapy 161 Department of Plastic, Reconstructive and Maxillo-Facial Surgery 164 Department of Primary Health Care 165 Department of Psychiatry and Mental Health 169 Department of Public Health 176 Department of Radiation Oncology 182 Department of Radiology 186 Department of Surgery 191 Department of Urology 196 HSRC/UCT Centre for Gerontology 198 FACULTY OF HEALTH SCIENCES Dean: Professor N Padayachee Director of Research: Prof A Azad Acting Director of Educaton: N Hartman Directors of Schools: Prof D Power - Child and Adolescent Health Prof A Miller - Deputy Child and Adolescent Health A/Prof R Watson - Allied Health Sciences Prof I Parker - Basic and Applied Sciences Prof J Myers - Public Health INTRODUCTION The University of Cape Town has long been recognised as the pre-eminent centre for medical research in South Africa and on the African continent.
    [Show full text]